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Background
Glycation is a common post-translational modification of
proteins, resulting from the chemical reaction between
reducing sugars such as glucose and the primary amino
groups on protein [1]. This non-enzymatic glycosylation
reaction generates structural heterogeneity in recom-
binant IgG1 antibodies produced by cell culture processes
[2]. Recent analytical characterization of a full-length
humanized antibody secreted by Chinese Hamster Ovary
(CHO) cells revealed that glycation of this protein occurs
predominantly at lysine 49 on the light chain of the anti-
body [3]. This finding contrasts with historical data that
have suggested that glycation sites are typically located
randomly at all accessible lysine residues distributed over
the entire molecule [2,3].
The glycated species accounted for 40–50% of the total
antibody produced by transient CHO cell transfections in
bioreactors. By contrast, other recombinant antibody
molecules produced by CHO cultures generally showed
only ~5% glycation [3]. This work documents cell culture
process development efforts taken to reduce glycation of
this antibody in stably expressing CHO cell lines.
Results
Early stable antibody expression by different CHO clones
in 60 mm plates demonstrated no significant differences
in glycation (see Table 1). This supports the expectation
that glycation of this antibody is an extracellular event
such that glycation levels should depend on cell culture
conditions and should not vary from clone to clone.
Antibody glycation was ~40–60% in 40L bioreactors and
~10–15% in 1L spinners at the time of harvests (see Table
2). Since the extent of this chemical modification should
increase with reaction time and substrate availability, the
considerable disparity in glycation between bioreactor
and spinner samples is attributed partly to the differences
in cultivation time and glucose concentrations.
The results from plate and spinner experiments show that
the glycation of this antibody can be reduced to below
40%. Hence, 2L bioreactor experiments were conducted
to test the feasibility of lowering glycation by reducing the
glucose concentration in the culture medium. The pH,
dissolved oxygen, and temperature profiles were control-
led identically in all the 2L bioreactors. The extent of gly-
cation in the bioreactor samples collected at the end of
culture (day 14) was determined using a boronate affinity
chromatographic method previously described [3].
In the first series of bioreactor experiments, the glucose
concentration in the batch feed was lowered by ~67%,
and the amount of supplemental glucose added was
reduced by ~50%. These modifications lowered glycation
to 14–20% for each of the three antibody stably-express-
ing clones tested (see Table 3). Subsequent bioreactor
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experiments employed clone 2 exclusively, and this
reduced glucose feed process was used as the control.
In the second set of bioreactor experiments, antibody gly-
cation was further reduced to ~10% (see Table 3) by elim-
inating glucose from the batch feed and replacing it with
a continuous glucose feed. In the final round of bioreactor
experiments, by using glucose-free inoculation medium
and batch feed, and by implementing a continuous glu-
cose feed strategy to maintain glucose at even lower con-
centrations throughout the culture, the glycated species
was minimized to 6% (see Table 3). Despite the variation
in antibody glycation, product titers and cell-specific pro-
ductivities were comparable in all the 2L bioreactor exper-
iments.
Conclusion
The percentage of glycated antibody was reduced by low-
ering the glucose concentration in the culture medium.
The extent to which glucose concentration in the cultures
was controlled directly impacted the antibody glycation
level.
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Table 3: Glycation of antibody produced in the first, second, and third series of 2L bioreactor experiments. Each condition was 
evaluated in duplicate bioreactors. Data represents average ± standard deviation obtained from duplicate cultures.
Experiment Clone Condition Glycation Final [Glucose]
1 2 Control 19 ± 2 % 2.9 ± 1.1 g/L
1 191 Control 17 ± 2 % 1.9 ± 0.4 g/L
1 274 Control 15 ± 1 % 1.4 ± 0.5 g/L
2 2 Control 16 ± 2% 1.8 ± 0.1 g/L
2 2 Partial Continuous Glucose Feed 10 ± 1% 0.8 ± 0.1 g/L
3 2 Control 19 ± 1% 2.2 ± 0.2 g/L
3 2 Full Continuous Glucose Feed 6 ± 0 % 0.5 ± 0.4 g/L
Table 2: Glycation of antibody produced in 40L bioreactors and 1L spinners.
Vessel Volume Clone Harvest Time Final [Glucose] Glycation
Bioreactor 2 x 40L 2 Day 11 and Day 14 > 9 g/L 42%
Bioreactor 40L 2 Day 14 > 10 g/L 58%
Bioreactor 40L 2 Day 14 > 7 g/L 42%
Spinner 1L 2 Day 5 < 6 g/L 13%
Spinner 1L 191 Day 5 < 6 g/L 11%
Table 1: Glycation of antibody produced by different CHO clones in 60 mm plates.
Clone 2 25 92 131 169 191 260 274 277
Glycation (%) 19 21 20 18 19 17 18 18 20Page 2 of 2
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